Novolizer Budesonide 200 micrograms inhalation powder

  • Name:

    Novolizer Budesonide 200 micrograms inhalation powder

  • Company:
    info
  • Active Ingredients:

    Budesonide

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 19/06/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 14/6/2019

Click on this link to Download PDF directly

Mylan IRE Healthcare Limited

Mylan IRE Healthcare Limited

Company Products

Medicine NameActive Ingredients
Medicine Name ALDARA 5% CREAM Active Ingredients Imiquimod
Medicine Name Ancotil 2.5g/250ml Solution for Infusion Active Ingredients Flucytosine
Medicine Name Brufen 400mg film-coated Tablets Active Ingredients Ibuprofen
Medicine Name Brufen 600mg film-coated tablets Active Ingredients Ibuprofen
Medicine Name Brufen Paediatric 100mg/5ml Oral Suspension Active Ingredients Ibuprofen
Medicine Name Brufen Retard 800mg prolonged release tablets Active Ingredients Ibuprofen
Medicine Name Calvidin 600mg/400IU Chewable Tablets Active Ingredients Calcium Carbonate, Colecalciferol (Vitamin D3)
Medicine Name Cibacen 10mg Film Coated Tablet Active Ingredients Benazepril Hydrochloride
Medicine Name Cibacen 5mg Film Coated Tablets Active Ingredients Benazepril Hydrochloride
Medicine Name Clozaril 100mg Tablets Active Ingredients Clozapine
Medicine Name Clozaril 25mg Tablets Active Ingredients Clozapine
Medicine Name Colifoam 10% w/w Rectal Foam Active Ingredients Hydrocortisone Acetate
Medicine Name Colofac 135mg Tablets Active Ingredients Mebeverine Hydochloride
Medicine Name Creon 10000 Gastro-resistant Capsules Active Ingredients Pancreatin
Medicine Name Creon 25000 Gastro-resistant Capsules Active Ingredients Pancreatin
Medicine Name Creon for Children 5000 Gastro-resistant Granules Active Ingredients Pancreatin
Medicine Name Cyklokapron 500mg Tablets Active Ingredients Tranexamic Acid
Medicine Name Dalmane 15mg Hard Capsules Active Ingredients Flurazepam monohydrochloride
Medicine Name Dalmane 30mg Hard Capsules Active Ingredients Flurazepam monohydrochloride
Medicine Name Desunin 4000IU Tablets Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name Desunin 800IU Tablets Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name DIFFLAM 3% CREAM Active Ingredients Benzydamine Hydrochloride
Medicine Name DIFFLAM ORAL RINSE Active Ingredients Benzydamine Hydrochloride
Medicine Name DIFFLAM SPRAY Active Ingredients Benzydamine Hydrochloride
Medicine Name Dona 1500mg Powder for Oral Solution Active Ingredients Glucosamine Sulfate, Sodium Chloride
1 - 0 of 95 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 14 June 2019 SmPC

Reasons for updating

  • Change to improve clarity and readability

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 19 June 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 19 June 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 26 January 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 26 January 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

$0In section4.2: Instructions for usage – addition of instructions for usage point 4$0$0In section5.1: Minor change – editing $0$0In section10: Date of revision changed.$0$0 $0

Updated on 26 January 2018 PIL

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

$0In section4.2: Instructions for usage – addition of instructions for usage point 4$0$0In section5.1: Minor change – editing $0$0In section10: Date of revision changed.$0$0 $0

Updated on 19 June 2017 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.4: Information regarding visual disturbance has been added.

In section 4.8: Blurred vision has been added to undesirable effects with frequency of not known

In section 10: The date of revision has been changed.

 

Updated on 19 June 2017 PIL

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 4.4: Information regarding visual disturbance has been added.

In section 4.8: Blurred vision has been added to undesirable effects with frequency of not known

In section 10: The date of revision has been changed.

 

Updated on 11 April 2017 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.5: Information regarding interaction with cobicistat-containing products has been added

In section 10: The date of revision has been changed.

Updated on 11 April 2017 PIL

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 4.5: Information regarding interaction with cobicistat-containing products has been added

In section 10: The date of revision has been changed.

Updated on 19 August 2016 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 2: Minor text addition.

In section 4.6: Information added regarding pregnancy.

In section 4.8: Changes in frequency of some side effects. Side effects added.

In section 10: Date of revision changed

Updated on 19 August 2016 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 2: Minor text addition.

In section 4.6: Information added regarding pregnancy.

In section 4.8: Changes in frequency of some side effects. Side effects added.

In section 10: Date of revision changed

Updated on 14 October 2013 PIL

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 4.2: change of text to refer to the elderly as ‘older people’

In section 4.8: Information on how to report adverse reactions and contact details of the IMB have been added

In section 10: The date of revision has been changed.

Updated on 14 October 2013 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.2: change of text to refer to the elderly as ‘older people’

In section 4.8: Information on how to report adverse reactions and contact details of the IMB have been added

In section 10: The date of revision has been changed.

Updated on 26 June 2013 PIL

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 4.5: the following text has been added; These patients may exhibit signs and symptoms of adrenal insufficiency when exposed to severe stress.

In section 4.6: the title has been changed to reflect the relevant SmPC structure

In section 4.8; small text changes has been made to the adverse table and reference to difficulty in swallowing has been replaced by throat irritation

In section 4.9: Additional information has been added

In section 10: the date of revision has changed

Updated on 26 June 2013 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.5: the following text has been added; These patients may exhibit signs and symptoms of adrenal insufficiency when exposed to severe stress.

In section 4.6: the title has been changed to reflect the relevant SmPC structure

In section 4.8; small text changes has been made to the adverse table and reference to difficulty in swallowing has been replaced by throat irritation

In section 4.9: Additional information has been added

In section 10: the date of revision has changed

Updated on 14 January 2013 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

·         In section 4.4; additional warnings and precautions for use have been added

·         In section 4.5: additional information has been added regarding interaction with other medicinal products. In this section some text has also been removed

·         In section 4.6: information has been expanded in relation to the use of budesonide in pregnancy and in breastfeeding

·         In section 4.7: information has changed to show that budesonide has no effect on the ability to drive and operate machinery

·         In section 4.8: the side effects table has been replaced and additional information has been added to this section. Information regarding the paediatric  population has been added

·         In section 4.9: the information regarding overdose has changed and the text in this section has been replaced with a single sentence which states that budesonide overdose is not expected to be a clinical problem

·         In section 6.5: information that the product has been packed in a polypropylene container sealed by aluminium foil is added. Additional refill pack information has been added also to this section

·         In section 10: the date of revision has changed

Updated on 14 January 2013 PIL

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

·         In section 4.4; additional warnings and precautions for use have been added

·         In section 4.5: additional information has been added regarding interaction with other medicinal products. In this section some text has also been removed

·         In section 4.6: information has been expanded in relation to the use of budesonide in pregnancy and in breastfeeding

·         In section 4.7: information has changed to show that budesonide has no effect on the ability to drive and operate machinery

·         In section 4.8: the side effects table has been replaced and additional information has been added to this section. Information regarding the paediatric  population has been added

·         In section 4.9: the information regarding overdose has changed and the text in this section has been replaced with a single sentence which states that budesonide overdose is not expected to be a clinical problem

·         In section 6.5: information that the product has been packed in a polypropylene container sealed by aluminium foil is added. Additional refill pack information has been added also to this section

·         In section 10: the date of revision has changed

Updated on 26 October 2011 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 2; the following statement is added - For a full list of excipients, see section 6.1
In section 4.4 the following text is addedand more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). 
In section 4.8; changes have been made to the table; another column has been added for 'Not known'
In section 7; the MA address has changed
In section 10; the date of revision has changed

Updated on 26 October 2011 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 2; the following statement is added - For a full list of excipients, see section 6.1
In section 4.4 the following text is addedand more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). 
In section 4.8; changes have been made to the table; another column has been added for 'Not known'
In section 7; the MA address has changed
In section 10; the date of revision has changed

Updated on 19 April 2011 SmPC

Reasons for updating

  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 9; the date of renewal has been changed to 1 June 2008
In section 10; the date of revision has changed to April 2011

Updated on 19 April 2011 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In all sections the name Novopulmon Novolizer has been changed to the correct brand name in IE - Novolizer Budesonide

Updated on 19 April 2011 PIL

Reasons for updating

  • Correction of spelling/typing errors

Free text change information supplied by the pharmaceutical company

In all sections the name Novopulmon Novolizer has been changed to the correct brand name in IE - Novolizer Budesonide

Updated on 19 April 2011 PIL

Reasons for updating

  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 9; the date of renewal has been changed to 1 June 2008
In section 10; the date of revision has changed to April 2011

Updated on 20 January 2011 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 20 January 2011 PIL

Reasons for updating

  • New SPC for medicines.ie

Free text change information supplied by the pharmaceutical company

None provided